Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer.

ABSTRACT: To date, there have not been great breakthroughs in immunotherapy for HER2 positive breast cancer (HPBC). This study aimed to build a risk model that might contribute to predicting prognosis and discriminating the immune landscape in patients with HPBC. We analyzed the tumor immune profile of HPBC patients from the TCGA using the ESTIMATE algorithm. Thirty survival-related differentially expressed genes were selected according to the ImmuneScore and StromalScore. A prognostic risk model consisting of PTGDR, PNOC and CCL23 was established by LASSO analysis, and all patients were classified into the high- and low-risk score groups according to the risk scores. Subsequently, the risk model was proven to be efficient and reliable. Immune related pathways were the dominantly enriched category.

SUBMITTER: Lin J 

PROVIDER: S-EPMC9166798 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature